Recital 11, Regulation (EU) 2024/2694

In forcesince 17 Oct 2024

The applicant declared that it held proprietary and exclusive rights of reference to the bioavailability study in rats, the in vitro bacterial reverse mutation assay, the in vivo micronucleus test, and the randomised, placebo-controlled human study, at the time it submitted the application, and that third parties cannot lawfully access, use or refer to those data.